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SUMMARY. Polycystic ovary syndrome (PCOS), a heterogeneous complex disease, is presented in the light of its
multifactorial pathogenesis. In particular, the genetic background of the syndrome and the most promising PCOS candi-
date genes are discussed in more detail.
Pregled
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SA@ETAK. Prikazan je sindrom policisti~nih jajnika (PCOS) kao heterogena kompleksna bolest, uglavnom iz vidika
njegove multifaktorske patogeneze. Genetska pozadina ovog sindroma i najvjerojatniji PCOS geni kandidati detaljno su
obrazlo`eni.
Clinical presentation of polycystic
ovary syndrome
Polycystic ovary syndrome (PCOS) is probably the
most common endocrinopathy in women of reproduc-
tive age. As a co-occurrence of polycystic ovary mor-
phology (PCO) and amenorrhoea, it was first described
by Stein and Leventhal in 1935. Nowadays, PCOS is
considered not only a syndrome of ovarian dysfunction
but a complex disorder with an extremely heterogenous
systemic clinical presentation. The prevalence of the
syndrome is estimated to be 5–10% in different ethnic
populations and as much as 22% of women in general
population have PCO on ultrasound.
1
PCOS accounts
for about three-quarters of all cases of anovulatory infer-
tility and for about 90% of the causes of hirsutism.
2
Ac-
cording to the 2003 Rotterdam Consensus criteria,
3
PCOS is diagnosed when, after the exclusion of other
possible etiologies (hyperprolactinemia, non-classical
congenital adrenal hyperplasia, androgen-secreting tu-
mors, Cushing’s disease, acromegalia), two out of three
of the following criteria are fulfilled: (i) chronic oligo-
or an-ovulation resulting in irregular menstrual cycles
(oligo- or amenorrhoea) with sub-/ infertility; (ii) clini-
cal hyperandrogenism (hirsutism, acne, androgenic alo-
pecia) and/or biochemical hyperandrogenism (hyper-
androgenemia); (iii) PCO on ultrasound (asymptomatic
PCO): the presence of 12 or more follicles measuring
2–9 mm in diameter, in both ovaries, and/or increased
ovarian volume (> 10 ml).
4
Regarding the above criteria,
three different PCOS phenotype subgroups should be
considered.
5
Other clinical and laboratory manifestations of PCOS
are: LH hypersecretion; metabolic disturbances: insulin






mature pubarche might be the earliest recognizable phe-
notype of PCOS.
8
As well as the short-term health impli-
cations for PCOS women, significant consequences for
long-term quality of life are evident: increased risk for




for endometrial cancer and for some other disorders.
1
Pathogenesis of PCOS
From the molecular point of view, the following pa-
thological changes have been observed in PCOS pa-
tients:
12
– abnormalities in biosynthesis, metabolism and/or
androgen action,
– disturbances in insulin secretion and/or action,
– disturbances in hypothalamic-pituitary pathway,
– changes in cortisol metabolism,
– lipid metabolism disturbances,
– chronic subclinic inflammatory processes.
However, the three major pathophysiologic hypothe-
ses for PCOS are the following:
13
1. Ovarian androgen hypothesis. Hyperandrogenism
is probably mainly the result of excessive biosynthesis
(predominantly in ovaries) and/or action of androgens.
It could affect hypothalamic control and pituitary go-
nadotropin secretion. In addition, increased local ovar-
ian androgen levels may impair follicular maturation
through direct effects on the follicles or by promoting
stromal hypertrophy/hyperplasia with stromal products
retarding follicular maturation.
A stable biochemical and molecular phenotype in
PCOS theca cells is evident. Enhanced production of
54
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dehydroepiandrosterone, progesterone, 17-hydroxypro-
gesterone and androstenedione was observed. Increased
steroidogenic activity is probably due to increased 3-hy-
droxysteroid-dehydrogenase and 17-hydroxylase/17,
20-lyase activities. Northern blot analysis revealed
that cytochrome P450 17-hydroxylase/17,20-desmolase
(CYP17) and cytochrome P450 side-chain cleavage en-
zyme (CYP11A) mRNAs were more abundant in PCOS
as compared to normal theca cells. In addition, transient
transfection experiments indicated that in PCOS theca
cells, the CYP17 promoter activity is enhanced.
14
2. LH hypothesis. Exaggerated LH pulse frequency
and amplitude could also reflect primary disturbances in
gonadotropin secretion, resulting in the stimulation of
ovarian androgen production as well as in anovulation.
3. Insulin hypothesis. Since insulin is postulated to
act as a cogonadotropin, increased serum insulin levels
could augment the stimulatory effect of LH on ovarian
androgen biosynthesis. Hyperinsulinemia could also di-
rectly stimulate ovarian androgen secretion or contrib-
ute to hyperandrogenism by suppressing hepatic sex-
hormone binding globulin (SHBG) production. Low se-
rum SHBG levels result in higher serum free (i.e. bio-
available) androgen levels. Similar effects on upregu-
lation of androgen biosynthesis have been described for
insulin-like growth factors.
Although most previous data suggest that ovarian an-
drogen hypersecretion (with subsequent abnormal LH
secretion, insulin resistance and anovulation) is the pri-
mary abnormality in the etiology of PCOS, the origin of
the whole spectrum of disturbances in PCOS is not yet
precisely determined and different pathways seem to be
in complex interactions.
15
Regarding extreme phenotypic heterogeneity of the
syndrome, multifactorial pathogenesis has been pro-
posed. Accordingly, the influence of a combination (in-
teraction) of several genetic (specific genotype combi-
nations) and/or environmental (nutrition, exercise) sus-
ceptibility factors have been considered.
1
Genetic basis of PCOS
A genetic contribution to the etiology of PCOS is
based on familial clustering of cases. There is no general
agreement on its mode of inheritance. However, due to
its extreme heterogeneity, PCOS is usually considered
to have an oligogenic (polygenic) rather than a mo-
nogenic basis: a minor contribution of several genes to
the final complexity of PCOS phenotype has been sug-
gested. Genetic susceptibility for PCOS differs between
individuals, even within affected families.
15
Recently, a
hypothesis on as early as prenatal genetic programming
of PCOS phenotype has been introduced.
16
Since the genome screen approach is impractical in
analyzing genetic background of complex diseases (such
as PCOS), the candidate gene approach is much more
widely used. Linkage analyses have been performed in
order to demonstrate the co-segregation of particular ge-
netic variants with disease loci. Association studies are
the most common approach and are used to investigate
whether a genetic variant of a candidate gene or a nearby
genetic marker is linked to a disease locus on a popula-
tion scale. Moreover, transmission/disequilibrium tests
have been performed to test whether parents who are
heterozygous for an allele hypothesized to be associated
with PCOS, transmit that allele more often to their af-
fected children than the non-disease transmitting allele.
17
Difficulties in analyzing the genetic background in
PCOS are mainly associated with the fact that PCOS is a
complex heterogeneous genetic disease with multifac-
torial pathogenesis: the results from different studies
cannot be readily compared, since different diagnostic
criteria are used. Therefore, large numbers of patients
with clear inclusion criteria should be tested to obtain
more reliable results. Moreover, PCOS is associated
with infertility, thus the availability of large pedigrees
for linkage analyses is limited. Also, a male phenotype
for PCOS has not yet been clearly defined, although pre-
mature male pattern baldness has been proposed.
18
PCOS candidate genes
On the basis of their known or expected role in the
pathogenesis of PCOS, numerous PCOS candidate ge-
nes have been proposed and studied till now.
1,2,15,17
At-
tention has been focused on defects in: (i) ovarian andro-
gen biosynthesis and action; (ii) insulin secretion and
action; (iii) hypothalamic-pituitary axis; (iv) adipose tis-
sue biochemical disturbances.
Till now, several nucleotide sequence changes, muta-
tions as well as genetic polymorphisms, have been shown
to influence transcriptional activity of target genes and
consequently, to be involved in the pathogenesis of
several human genetic diseases.
19
The most promising
PCOS candidate genes are introduced below.
Genes involved in ovarian androgen
production and action
Genes involved in ovarian androgen biosynthesis.
Increased transcriptional activity of genes encoding ste-
roidogenic enzymes could lead to upregulation of an-
drogen biosynthesis. The most widely studied PCOS
candidate genes from this group are CYP17 gene (cyto-
chrome P450 17-hydroxylase/17, 20-desmolase gene),
CYP21 gene (cytochrome P450 21-hydroxylase gene)
and CYP11A gene (cytochrome P450 side-chain cleav-
age enzyme gene) (15q23-q24).
The CYP11A gene product, cholesterol desmolase,
catalyzes a rate-limiting step in steroidogenesis. The
(TTTTA)
n
microsatellite polymorphism in the CYP11A
promoter was proposed as influencing CYP11A gene
transcriptional activity. In the initial study, evidence of a
weak linkage between the CYP11A gene and hyper-
androgenemia in PCOS women and a strong association
of the CYP11A microsatellite polymorphism with total
serum testosterone levels in PCOS patients were
55
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found.
20
Furthermore, an association between the poly-
morphism and the presence of PCOS in Greek patients
was confirmed.
21
However, a large multicentric study as
well as certain other studies, failed to find a significant
association between CYP11A gene and PCOS.
1
AR gene (androgen receptor gene) (Xq11-q12). Ge-
netically determined androgen receptor hypersensitivity
could result in clinical hyperandrogenism even in nor-
moandrogenemic PCOS patients. Microsatellite poly-
morphism (CAG)
n
in exon 1 of the AR gene has been
suggested as influencing AR transcriptional activity. Ini-
tially, no evidence for association of the polymorphism
(CAG)
n
with PCOS was provided.
22
However, the poly-
morphism was shown to be inversely correlated with se-
rum androgen levels.
23
In Australian patients, a signifi-
cantly higher frequency of longer CAG alleles in PCOS
compared to control women was found.
24
In contrast, an
association between shorter AR alleles and precocious
pubarche was found in Spanish girls.
25
However, results
of a recent study on Finnish PCOS patients led to the
conclusion that AR (CAG)
n
polymorphism is not a major
determinant of PCOS.
26




phism in the promoter of the SHBG gene might influ-
ence transcriptional activity of the SHBG gene. Conse-
quently, disturbed SHBG production and secretion with
further changes in serum bioavailable androgen levels
might occur. An association between SHBG alleles with
more than eight TAAAA repeats and PCOS as well as a
highly significant influence of the polymorphism on se-
rum SHBG levels were observed in different ethnic pop-
ulations, with longer alleles predisposing to lower se-
rum SHBG levels.
27,28
Genes involved in insulin secretion and action
INSR gene (insulin receptor gene) (19p13.2). Several
sequence analyses in the INSR gene have been per-
formed, but negative results were obtained. However,
increased insulin receptor serine phosphorylation in
skeletal muscle cells and fibroblasts has been described
in approximately 50% of PCOS women. Moreover, ty-
rosine autophosphorylation of the insulin receptor has
been found to be decreased in PCOS ovaries. An associ-
ation between PCOS and a C/T single nucleotide poly-
morphism in the INSR gene segment encoding tyrosine
kinase has been shown.
1
In addition, three separate stud-
ies have found linkage and an association between
D19S884 marker, located near the INSR gene at position
19p13.3, and PCOS.
29
Further evidence for probably im-
portant role of this region in the pathogenesis of PCOS
was provided by statistically significant linkage be-
tween the region and serum androgen levels in Cauca-
sians. However, the putative PCOS gene at this chromo-
somal location remains to be identified.
1
INS gene (insulin gene) (11p15.5). Minisatellite po-
lymorphism (VNTR) in the promoter of the INS gene
might influence transcriptional activity of the gene. Ini-
tially, strong linkage and association between class III
INS VNTR alleles and PCOS were found.
9
Afterwards,
no association between INS VNTR polymorphism and
the presence of PCOS was obtained in two separate
studies. In addition, no evidence of linkage of the INS
gene and PCOS as well as no association between class
III INS alleles and hyperandrogenemia was found in a
larger study.
30
IRS-1 gene (2q36), IRS-2 gene (13q34). The IRS
genes encode for insulin receptor substrates (IRSs) that
are critical proteins for signal transduction in insulin tar-
get tissues. Despite some promising results, no convinc-
ing evidence for involvement of IRSs in the patho-
genesis of PCOS has been reported.
1
CAPN10 gene (2q37.3). The CAPN10 gene encodes
for calpain 10, an ubiquitously expressed member of a
calpain-like cysteine protease family. It affects insulin
action and has been described as being associated with
an increased likelihood of developing type II diabetes
mellitus. However, no obvious involvement of CAPN10
polymorphic variants in the development of PCOS has
been reported.
1
IGF2 gene (11p15.5). The IGF2 gene encodes for in-
sulin-like growth factor II, which stimulates insulin ac-
tion as well as adrenal and ovarian androgen secretion.
A G/A single nucleotide polymorphism on position
+582 relative to termination codon has been described
as influencing IGF2 gene expression. The G alleles are
reported to increase IGF2 mRNA levels in leukocytes
and probably result in increased IGF2 expression and
secretion in liver. An association study on Spanish pa-
tients showed a significantly higher frequency of IGF2
G/G homozygotes in PCOS compared to control wo-
men.
31
Genes involved in gonadotropin release,
regulation and action
LH gene (19q13.32). Since increased serum LH (lu-
teinizing hormone) levels are frequently observed in
PCOS patients, possible LH gene abnormalities have
been sought. Indeed, a variant with two point mutations,
functionally different from the wild type, has been
found in PCOS women, but its role in the pathogenesis
of PCOS is considered not to be pivotal.
1
LH receptor gene (2p21). The presence of LH recep-
tor gene mutations has been examined in PCOS patients
with normal serum LH levels and hyperandrogenemia.
No mutations were found in two different studies. How-
ever, a linkage analysis in five affected families showed
segregation of polymorphic markers, close to the LH re-
ceptor gene, with PCOS.
1
FST gene (5q11.2). Since activin plays an important
role in follicular maturation and regulation of ovarian
androgen production, excessive neutralization of activin
by follistatin, its binding protein, may result in the
PCOS phenotype. Although a strong linkage between
the gene encoding follistatin (FST gene) and PCOS has
56
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been reported,
17
no PCOS susceptibility genetic variants
have been found.
1
Genes involved in adipose tissue metabolism
Several other genes, including those involved in adi-
pose tissue metabolism, have been proposed as PCOS
candidate genes. Genetic variants in the leptin gene
(7q31.3), leptin receptor gene (1p31), in the gene en-
coding peroxisome proliferator-activated receptor -
PPAR gene (3p25), in the adiponectin gene (3q27), in
the gene encoding plasminogen activator inhibitor-1-
PAI-1 gene (7q21.3-q22) and in many other genes have




Recent cDNA microarray analyses have shown con-
sistent differences in gene expression profiles between
human PCOS and normal ovarian theca cells. Accord-
ingly, several new PCOS candidate genes, involved in
different biological pathways and being either over-ex-
pressed or down-regulated in PCOS patients, might be
proposed.
32–36
Examples are genes encoding proteins in-
volved in Wnt signalling, proteins involved in apoptosis
and stress response, components and remodelling fac-
tors of extracellular matrix, components of the immune
system, heat shock proteins, proteins with a role in pro-
liferation and differentiation. Data from microarray
analyses may contribute to a better understanding of ab-
normal biochemical pathways in PCOS and to novel
clues for ovarian dysfunction in PCOS. Consequently,
novel leads for therapeutic interventions might be ap-
plied in future.
Conclusion
Despite extensive investigations, the pathogenesis of
PCOS remains only partly elucidated. Results from nu-
merous studies on PCOS candidate genes are contradic-
tory, suggesting that specific PCOS susceptibility genes
or regions have yet to be identified. To overcome some
of the limitations in studying the genetic background of
PCOS, large multicentric studies should be performed
and statistical methods that were developed especially
for complex diseases should be applied.
37
Regarding extreme heterogeneity of the syndrome, a
combination of specific genetic polymorphisms might
be indirectly involved in the PCOS clinical status. New
molecular genetic approaches, such as microarray tech-
nology, hold promise for elucidating pathophysiological
mechanisms of several human diseases, including
PCOS. Successful identification of PCOS candidate
genes would have enormous potential for both the diag-
nosis and management of PCOS. The prospect arises of
being able to identify genetic susceptibility loci in indi-
vidual patient profiles to aid diagnosis, highlight
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